Literature DB >> 15154843

Modified-vaccinia-virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T-cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach.

Dania Vázquez-Blomquist1, Diógenes Quintana, Carlos A Duarte.   

Abstract

A prime-boost strategy combining FWPV (fowlpox virus) and the MVA (modified vaccinia virus Ankara), both expressing HIV-1 multi-V3 epitope polypeptides, was compared with a DNA-based Semliki Forest virus replicon/poxvirus approach for the induction of a CD8(+) T-cell response. Priming mice with recombinant MVA and boosting with recombinant FWPV, and not in the reverse order, increased the number of specific interferon-gamma-secreting cells in relation to the homologous combinations. Moreover, the improvement of the CD8(+) T-cell response with this combination was remarkably higher than that obtained by priming with a DNA vector containing a Semliki Forest virus replicon expressing the multi-epitope polypeptide and boosting either with recombinant MVA or FWPV. These results open a new and attractive alternative for vaccine preparation against HIV-1 using different immunogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154843     DOI: 10.1042/BA20030176

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  2 in total

1.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

2.  Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2.

Authors:  Junu A George; Seong Kug Eo
Journal:  Immune Netw       Date:  2011-10-31       Impact factor: 6.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.